Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company based in Westlake Village, California, specializing in developing and commercializing treatments for dermatological diseases. Founded in 2016, Arcutis leverages recent advances in immunology and inflammation to create differentiated therapies targeting immune-mediated dermatological conditions.
Arcutis' lead product, ZORYVE (roflumilast) cream, is a topical treatment for plaque psoriasis and atopic dermatitis. The company has recently launched ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis. Both formulations utilize roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor that has shown significant improvement in clinical trials.
Arcutis is also advancing its pipeline with ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema, and ARQ-255 for alopecia areata. The company champions meaningful innovation to address the urgent needs of patients living with chronic, immune-mediated skin conditions, aiming to improve treatment options and patient outcomes.
In recent developments, Arcutis has been actively participating in industry conferences, securing strategic collaborations, and expanding its workforce. The company's financial health is robust, with a strong cash position bolstered by a recent public offering and a strategic licensing agreement in Japan. Arcutis continues to focus on long-term growth and innovation, with multiple ongoing clinical programs targeting various inflammatory dermatological conditions.
For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Arcutis Biotherapeutics (Nasdaq: ARQT) will present five abstracts at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference from June 8-10, 2024, in Chicago, IL. The presentations include new long-term safety and efficacy data of roflumilast cream 0.15% for mild to moderate atopic dermatitis in patients aged 6 and above. Preclinical data on ARQ-234, a CD200 receptor agonist for atopic dermatitis, will also be showcased. Additional presentations will cover the consistent tolerability profile of topical roflumilast in psoriasis, seborrheic dermatitis, and atopic dermatitis. The company aims to advance the standard of care for chronic, immune-mediated skin diseases.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference from June 10-13, 2024. The event will feature a fireside chat on June 12 at 1:20 pm ET, accessible via webcast on the company's website. The replay will remain available for 180 days post-conference. Arcutis specializes in innovations in immuno-dermatology, aiming to provide significant advancements in this field.
Arcutis Biotherapeutics reported a strong performance in Q1 2024, with net product revenues of $21.6M for its ZORYVE® franchise, showing a 675% year-over-year growth. ZORYVE cream and foam contributed $15M and $6.5M, respectively. The company expects further GTN improvements and is preparing for a key FDA decision on July 7, 2024, regarding roflumilast cream for treating atopic dermatitis. Arcutis raised $172.5M from a public offering and secured a strategic licensing agreement in Japan. The company also reported a net loss of $35.4M, an improvement from the $80.1M loss in Q1 2023.
Arcutis Biotherapeutics, Inc. announced the validation of ZORYVE foam for treating Seborrheic Dermatitis across diverse hair types. A panel of experts expressed confidence in prescribing the foam for various skin and hair types based on formulation data. The use of Crodafos CES in the formulation makes ZORYVE suitable for all affected body areas, highlighting its versatility and efficacy. The company received positive feedback from the expert panel, affirming the gentle and effective nature of the foam for patients with different hair and skin types.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) granted restricted stock units and options to 13 new employees as an inducement for joining the company. The awards were approved by the Compensation Committee of Arcutis' Board of Directors and are part of the 2022 Inducement Plan. The grants are subject to vesting conditions over four years, with stock options having a ten-year term and an exercise price of $8.84 per share.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report first quarter 2024 financial results on May 14, 2024, after the U.S. financial markets close. The company will also provide a business update and host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation material on the company's website.
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
What does Arcutis Biotherapeutics, Inc. specialize in?
What are the main products of Arcutis Biotherapeutics?
Where is Arcutis Biotherapeutics headquartered?
When was Arcutis Biotherapeutics founded?
What is ZORYVE?
What is the mechanism of action for ZORYVE?
What are Arcutis' latest achievements?
How is Arcutis ensuring long-term growth?
What are some of Arcutis' ongoing projects?
Where can I get more information about Arcutis Biotherapeutics?
